PLASMA LEVELS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN PATIENTS WITH TYPE 2 DIABETES AFTER LIPOPOLYSACCHARIDE INJECTION

被引：0
|
作者：
Berg, R. M. G. [1 ]
Andreasen, A. S. [1 ]
Pedersen, B. K. [1 ]
Moller, K. [1 ,2 ]
机构：
[1] Univ Copenhagen Hosp, Rigshosp, Ctr Inflammat & Metab, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen Hosp, Rigshosp, Intens Care Unit 4131, DK-2100 Copenhagen, Denmark
来源：
INTENSIVE CARE MEDICINE | 2009年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
0947
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [41] The role of the platelet pool of Plasminogen Activator Inhibitor-1 in well-controlled type 2 diabetes patients
    Mossberg, Karin
    Olausson, Josefin
    Fryk, Emanuel
    Jern, Sverker
    Jansson, Per-Anders
    Brogren, Helen
    PLOS ONE, 2022, 17 (08):
  • [42] Dapagliflozin reduces plasma concentration of plasminogen activator inhibitor-1 in patients with heart failure with preserved ejection fraction and type 2 diabetes
    Dziewierz, Artur
    Zabojszcz, Michal
    Natorska, Joanna
    Slusarczyk-Dolecka, Magdalena
    Kuleta, Martyna
    Siudak, Zbigniew
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2022, 132 (12):
  • [43] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Chung, HC
    Rha, SY
    Park, JO
    Yoo, NC
    Kim, JH
    Roh, JK
    Min, JS
    Lee, KS
    Kim, BS
    Kim, JJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (01) : 41 - 50
  • [44] Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
    Sakurai, Shintaro
    Jojima, Teruo
    Iijima, Toshie
    Tomaru, Takuya
    Usui, Isao
    Aso, Yoshimasa
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (11)
  • [45] SULFONYLUREA THERAPY AND PLATELET PLASMINOGEN-ACTIVATOR INHIBITOR-1 RELEASE IN PATIENTS WITH TYPE-2 DIABETES
    JOKL, R
    COLWELL, JA
    DIABETOLOGIA, 1994, 37 : A24 - A24
  • [46] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Hyun Cheol Chung
    Sun Young Rha
    Joon Oh Park
    Nae Choon Yoo
    Joo Hang Kim
    Jae Kyung Roh
    Jin Sik Min
    Kyong Sik Lee
    Byung Soo Kim
    Jin Ju Kim
    Breast Cancer Research and Treatment, 1998, 49 : 41 - 50
  • [47] Plasminogen activator inhibitor-1
    Gils, A
    Declerck, PJ
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2323 - 2334
  • [48] Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients
    Fogari, R
    Mugellini, A
    Zoppi, A
    Corradi, L
    Preti, P
    Lazzari, P
    Derosa, G
    AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (04) : 316 - 320
  • [49] RELATION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 CONCENTRATION IN DIFFERENT PLASMA SAMPLES
    SIEGERT, G
    FRITZ, T
    RUNGE, E
    FIBRINOLYSIS, 1994, 8 : 154 - 156
  • [50] Plasminogen activator inhibitor-1 is associated with coronary artery calcium in type 1 diabetes
    Pratte, Katherine A.
    Hokanson, John E.
    Eckel, Robert H.
    Snell-Bergeon, Janet K.
    Rewers, Marian J.
    DIABETES, 2006, 55 : A162 - A162
12345